Drugs / NGI226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05592990 | Jun 2023 → Feb 2026 | disease of the tendon | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGI226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05592990 ↗ |
| Route | Other | “single peritendon injection” NCT05592990 ↗ |